68Ga-NK224 PET/CT 显示非小细胞肺癌 PD-L1 肿瘤内与肿瘤间异质性
前瞻性研究纳入48例新诊断或复发/转移性非小细胞肺癌患者,行68Ga-NK224 PET/CT并与PD-L1免疫组化对照。结果显示活检层面SUVmax与TPS强相关(ρ=0.80),判别高PD-L1表达的最佳SUVmax阈值为5.6。68Ga-NK224 PET/CT可整体评估PD-L1异质性,且摄取水平与免疫治疗病灶反应相关。
要点
- 68Ga-NK224 PET/CT可全身评估PD-L1表达异质性,避免单点活检取样偏差。
- SUVmax临界值5.6可用于判别高PD-L1表达肿瘤。
- 免疫治疗有效病灶的68Ga-NK224摄取明显高于进展或稳定病灶。
核心结论
- 68Ga-NK224 PET/CT可整体评估NSCLC中PD-L1异质性,揭示了活检未能捕捉的病灶水平异质性,且摄取与免疫治疗反应相关。
研究设计与样本
- 前瞻性研究,2023年12月至2025年7月纳入48例新诊断或复发/转移性NSCLC患者。
- 所有参与者行68Ga-NK224 PET/CT及PD-L1免疫组化分析,以PD-L1 TPS为参考标准。
- 采用活检层面ROI及全病灶ROI两种方式量化SUVmax。
关键影像表现/征象
- 68Ga-NK224摄取在PD-L1 TPS不同分类组间存在差异。
- 免疫组化判定为PD-L1阴性的12例中,5例至少有一个病灶SUVmax超过5.6阈值(共68个病灶中15个)。
- 全病灶ROI评估的肿瘤内异质性显著高于活检层面ROI。
- 个体内部肿瘤间异质性明显,SUVmax变异系数中位数为23.6%。
诊断标准与关键数值
- 判别高PD-L1表达肿瘤的最佳SUVmax阈值为5.6。
- 活检层面SUVmax与TPS强相关,Spearman ρ=0.80(P<.001)。
- 免疫治疗中部分或完全缓解病灶(缩小≥30%)的SUVmax中位数为5.9,进展或稳定病灶为1.9(P=.01)。
临床应用与阅片要点
- 68Ga-NK224 PET/CT可用于免疫治疗前全身性PD-L1评估,弥补单灶活检局限。
- 报告时应关注活检层面与全病灶SUVmax的差异,提示肿瘤内异质性时以全病灶评估为准。
- 多发病灶间的SUVmax变异情况可作为肿瘤间异质性的重要观察指标。
局限性
- 单中心前瞻性研究,样本量为48例。
- 以PD-L1免疫组化TPS为参考标准,未报告与疗效预测相关的长期生存终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Programmed death ligand 1 (PD-L1) expression assessed via immunohistochemical analysis of single-site biopsies is standard for guiding immunotherapy in non-small cell lung cancer (NSCLC). However, this approach fails to capture intra- and intertumoral heterogeneity. Purpose To investigate whether gallium 68 (68Ga) NK224 PET/CT enables whole-body assessment of PD-L1 expression and heterogeneity in NSCLC and whether lesion-specific treatment response is associated with PET-defined PD-L1 uptake. Materials and Methods In this prospective study conducted from December 2023 to July 2025, participants with newly diagnosed or recurrent or metastatic NSCLC underwent 68Ga-NK224 PET/CT and PD-L1 immunohistochemical analysis. Tumor uptake of 68Ga-NK224 was quantified using maximum standardized uptake value (SUVmax) from biopsy-plane regions of interest (ROIs) and whole-lesion ROIs. PD-L1 tumor proportion score (TPS) was the reference standard. Intratumoral heterogeneity was assessed using the normalized range of SUVmax, and intertumoral heterogeneity was evaluated using the SUVmax coefficient of variation across lesions. Results This study included 48 participants (median age, 68 years [IQR, 59-75 years]; 31 men). Across 52 lesions, 68Ga-NK224 uptake differed among PD-L1 TPS categories (P < .001), and biopsy-plane SUVmax correlated strongly with TPS (Spearman ρ = 0.80; P < .001). Receiver operating characteristic analysis identified an optimal SUVmax cutoff of 5.6 for discriminating tumors with high PD-L1 expression. Among 12 participants classified as PD-L1 negative via immunohistochemical analysis, five had one or more lesions with SUVmax above the cutoff (15 of 68 lesions). Intratumoral heterogeneity was substantially higher when assessed using whole-lesion ROIs (median normalized range, 1.0) versus biopsy-plane ROIs (median normalized range, 0.4) (P < .001). Intertumoral heterogeneity within individual participants was pronounced (median SUVmax coefficient of variation, 23.6% [IQR, 17.9%-36.7%]). In participants receiving immunotherapy (24 lesions), lesions with partial or complete response (shrinkage ≥30%; median shrinkage, 47.5%) showed greater 68Ga-NK224 uptake than lesions with progressive or stable disease (shrinkage <30%; median shrinkage, 7.4%) (median SUVmax, 5.9 vs 1.9; P = .01). Conclusion 68Ga-NK224 PET/CT enabled whole-body assessment of PD-L1 heterogeneity in NSCLC and revealed lesion-level heterogeneity not captured through biopsy, and uptake was associated with immunotherapy response. Clinical trial registration no. NCT06754345 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Lopci in this issue.
引用
- Zhao, Zhou, Yu, et al. 68Ga-NK224 PET/CT Reveals Intra- and Intertumoral Heterogeneity of PD-L1 in Non-Small Cell Lung Cancer. Radiology. 2026. PMID: 42610817. doi:10.1148/radiol.260372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。